자료유형 | 학위논문 |
---|---|
서명/저자사항 | Translating the Anti-Tumor/Anti-Cachectic Activity of AR-42, a Novel HDAC Inhibitor, into Pancreatic Cancer Therapy. |
개인저자 | Henderson, Sally Erin. |
단체저자명 | The Ohio State University. Comparative and Veterinary Medicine. |
발행사항 | [S.l.]: The Ohio State University., 2017. |
발행사항 | Ann Arbor: ProQuest Dissertations & Theses, 2017. |
형태사항 | 153 p. |
기본자료 저록 | Dissertations Abstracts International 81-05B. Dissertation Abstract International |
ISBN | 9781687947734 |
학위논문주기 | Thesis (Ph.D.)--The Ohio State University, 2017. |
일반주기 |
Source: Dissertations Abstracts International, Volume: 81-05, Section: B.
Advisor: Chen, Ching-Shih. |
이용제한사항 | This item must not be sold to any third party vendors. |
요약 | Pancreatic cancer is the 3rd leading cause of cancer death in the United States and has a 5-year survival of less than 9% for all stages. Furthermore, cachexia, defined as severe weight loss due to depletion of muscle mass that is not reversible with conventional nutritional support, is seen in 85% of pancreatic cancer patients and contributes significantly to morbidity and mortality. Therefore, there is an urgent need to develop novel therapeutics that target tumor growth and muscle wasting in order to improve clinical outcomes. The first part of this study was aimed at evaluating the efficacy of AR-42, a novel histone deacetylase (HDAC) inhibitor developed in our laboratory, in suppressing tumor growth in mouse models of pancreatic cancer. The in vitro anti-proliferative activity of AR-42 was evaluated in six human pancreatic cancer cell lines. An AsPC-1 subcutaneous xenograft and transgenic KPfl/flC (LSL-KrasG12D |
일반주제명 | Pharmacology. Cellular biology. Molecular biology. |
언어 | 영어 |
바로가기 |
: 이 자료의 원문은 한국교육학술정보원에서 제공합니다. |